Filing summary: AmpliPhi Biosciences Corporation, Q1 2015
Identity note: The request identifies Armata Pharmaceuticals, Inc., but the supplied 10-Q is filed by AmpliPhi Biosciences Corporation. Verify the intended issuer before relying on this summary.
Business context and reporting period
This unaudited Form 10-Q covers the three months ended March 31, 2015, with comparisons to Q1 2014. AmpliPhi was a development-stage biotechnology company developing bacteriophage therapies for bacterial infections, including candidates targeting P. aeruginosa, MRSA, and C. difficile. It reported no product revenue; reported revenue came from sublicensing agreements related to a former gene-therapy program.
Key financial metrics
| Metric | Q1 2015 / March 31, 2015 | Comparable period / prior year-end |
|---|---|---|
| Revenue | $102,000 | $104,000 in Q1 2014 |
| Research and development expense | $972,000 | $1.011 million in Q1 2014 |
| General and administrative expense | $1.397 million | $1.627 million in Q1 2014 |
| Operating loss | $2.267 million | $2.534 million in Q1 2014 |
| Net loss | $14.493 million | $11.307 million in Q1 2014 |
| Net loss attributable to common stockholders | $14.831 million; $0.07 per share | $11.621 million; $0.06 per share |
| Cash used in operating activities | $2.305 million | $3.691 million in Q1 2014 |
| Cash and cash equivalents | $16.625 million | $6.581 million at December 31, 2014 |
| Total assets | $38.604 million | $28.617 million at December 31, 2014 |
| Total liabilities | $39.352 million | $23.190 million at December 31, 2014 |
| Stockholders’ equity (deficit) | $(3.076) million | $3.437 million at December 31, 2014 |
Operating expenses exceeded revenue in both periods, and the filing reports no positive operating margin. The Q1 2015 net loss included an $11.795 million non-cash loss from remeasurement of warrant and preferred-stock conversion liabilities, plus $431,000 of other expense. Current assets were $17.038 million against current liabilities of $2.122 million. The filing does not report conventional borrowings as a key funding source; significant liabilities included $19.425 million for the preferred-stock conversion feature and $14.727 million for warrants.
Material changes versus the prior comparable period
- Revenue was essentially flat year over year. R&D expense decreased about 4%, and G&A expense decreased about 14%, improving the operating loss by $267,000.
- Net loss increased by $3.186 million, mainly because the fair-value loss on warrant and derivative liabilities rose to $11.795 million from $8.773 million.
- Operating cash use improved by $1.386 million year over year. Cash increased by $10.044 million during the quarter, principally reflecting financing proceeds.
- In March, the company raised $13.0 million gross by issuing 78.8 million common shares at $0.165 per share, together with warrants. The cash-flow statement reports $12.384 million of net financing cash. Shares outstanding rose to 277.9 million at quarter-end from 199.2 million at December 31, 2014.
Outlook, risks, contingencies, and unusual items
- Management estimated that the March financing and available cash would fund operations through the second quarter of 2016. It also stated that existing funds would not cover all required product development and that additional financing would be needed; availability and terms were uncertain.
- The company expected significant operating losses to continue for several years, R&D expense to increase in 2015, and G&A expense to rise with planned staffing and a new CEO. It did not expect product revenue in the near term.
- Failure to obtain financing could require delaying or reducing research programs, selling or licensing assets, or other significant changes; the filing says insufficient funding raises uncertainty about continued operations.
- Warrants and the preferred-stock conversion feature were Level 3 fair-value liabilities using significant unobservable inputs. Their remeasurement can materially affect reported earnings without a corresponding operating cash outflow.
- New financing warrants included contingent cash liquidated damages of $2.5 million if the company failed to authorize enough common shares or effect a reverse split to permit full exercise. On May 8, 2015, the company agreed with holders representing more than two-thirds of certain earlier warrants to remove specified down-round protections; reclassification depended on authorizing sufficient shares.
- After quarter-end, AmpliPhi announced M. Scott Salka as CEO, effective May 18, 2015. The filing reported no legal proceedings expected to have a material adverse effect and no material changes to previously disclosed risk factors.
Most important facts for investors to verify
- Confirm the issuer: the supplied filing is for AmpliPhi Biosciences Corporation, not Armata Pharmaceuticals, Inc.
- Check subsequent cash usage and financing against management’s stated runway through Q2 2016, including the assumptions behind that estimate.
- Assess dilution from the March share issuance, associated warrants, Series B conversion rights, and the company’s ability to authorize enough shares for warrant exercise.
- Review the valuation assumptions and potential earnings volatility of the Level 3 warrant and preferred-stock conversion liabilities, including the effect of the May 2015 warrant amendment.
- Track clinical-development progress, expected R&D spending, and the timing and terms of any further capital raise.